Display options
Share it on

J Med Chem. 2018 Mar 08;61(5):1774-1784. doi: 10.1021/acs.jmedchem.7b01298. Epub 2017 Oct 31.

Fragment-to-Lead Medicinal Chemistry Publications in 2016.

Journal of medicinal chemistry

Christopher N Johnson, Daniel A Erlanson, Wolfgang Jahnke, Paul N Mortenson, David C Rees

Affiliations

  1. Astex Pharmaceuticals , 436 Cambridge Science Park, Milton Road , Cambridge CB4 0QA , United Kingdom.
  2. Carmot Therapeutics Inc. , 740 Heinz Avenue , Berkeley , California 94710 , United States.
  3. Novartis Institutes for Biomedical Research, Chemical Biology and Therapeutics , 4002 Basel , Switzerland.

PMID: 29087197 DOI: 10.1021/acs.jmedchem.7b01298

Abstract

The popularity of fragment-based drug discovery (FBDD) is demonstrated by the number of recent successful fragment-to-lead (F2L) publications. This Miniperspective provides a tabulated summary of the F2L literature published in the year 2016, along with discussion of general trends. It uses the same format as our summary of the 2015 literature and is intended to be a resource for both FBDD practitioners and medicinal chemists in general.

Substances

MeSH terms

Publication Types